Arcutis Biotherapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA for ZORYVE® (roflumilast) cream 0.05%, seeking to extend its use for treating mild to moderate atopic dermatitis in infants as young as 3 months. This initiative addresses a critical gap in pediatric dermatology, as atopic dermatitis often manifests in infancy, affecting approximately 1 million children under the age of 2 in the U.S. Currently, treatment options are limited, with only one other FDA-approved topical non-steroidal anti-inflammatory agent available for this vulnerable demographic.

The INTEGUMENT-INFANT Phase 2 study demonstrated that ZORYVE cream was well tolerated in infants, with a safety profile consistent with that observed in older children and adults. Key findings from the trial included that 34.4% of infants achieved a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) success at four weeks, and 58.3% achieved at least a 75% reduction in eczema severity (EASI-75). The cream’s formulation is specifically designed for pediatric use, addressing the unique skin barrier and immune system considerations in infants. This could significantly reduce reliance on topical steroids, which are often a concern for caregivers due to potential long-term side effects.

The potential approval of ZORYVE cream for infants could shift the treatment paradigm for atopic dermatitis in this age group, providing a non-steroidal, effective, and well-tolerated option. This development may accelerate research into similar formulations targeting other inflammatory skin conditions in young children, ultimately expanding the therapeutic landscape for pediatric dermatology and improving quality of life for affected families.

Source: globenewswire.com